MedTrace Logo

Theranostic PET for Target Validation and Tumor Detection

NCT07664410 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-06-24

No results posted yet for this study

Summary

Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department.

The aim of this study is to collect data on the expression of target molecules/receptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET/CT or PET/MRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions.

Primary Endpoint:

Association between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.

Conditions

  • Solid Malignancies

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • David Kersting, MD PhD · University Hospital, Essen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-23
Primary Completion
2035-09-23
Completion
2035-09-23

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664410 on ClinicalTrials.gov